Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
ASTRO concerned about proposed Medicare physician payment cuts to radiation therapy

ASTRO concerned about proposed Medicare physician payment cuts to radiation therapy

The American Society for Radiation Oncology is concerned about proposed additional payment cuts to radiation therapy detailed in the Centers for Medicare and Medicaid Services' proposed Medicare Physician Fee Schedule (MPFS), released July 8, 2015, which will take effect on January 1, 2016. [More]
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
SCCA named among nation's best for adult cancer care

SCCA named among nation's best for adult cancer care

Seattle Cancer Care Alliance has been named among the best in the nation for adult cancer care by U.S. News & World Report. The 2015-2016 U.S. News Best Hospitals ranking specifically cited care provided by the University of Washington Medical Center, one of SCCA's three founding partners. [More]
Stem cell transplantation improves outcomes in children with rare form of chronic blood cancer

Stem cell transplantation improves outcomes in children with rare form of chronic blood cancer

Researchers in the Division of Hematology, Oncology and Blood & Marrow Transplantation at Children's Hospital Los Angeles have shown greatly improved outcomes in using stem cell transplantation to treat patients with a serious but very rare form of chronic blood cancer called juvenile myelomonocytic leukemia (JMML). [More]
Moffitt researchers develop genetic test that analyzes sensitivity of tumors to radiation therapy

Moffitt researchers develop genetic test that analyzes sensitivity of tumors to radiation therapy

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy. [More]
New Histone Antibody Specificity Database allows scientists to find right antibodies for biomedical research

New Histone Antibody Specificity Database allows scientists to find right antibodies for biomedical research

For years, a crisis has been brewing in molecular biology. The problem is that antibodies--research tools used to identify key proteins at work in a cell--aren't always what they seem. Unreliable antibodies have led to numerous instances of false findings, failed experiments, and wasted money and samples. [More]
Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

The Gladstone Institutes announces the creation of Cure Network Ventures Inc. and Cure Network Dolby Acceleration Partners, LLC, a business endeavor with Dolby Family Ventures and Evotec AG, which will focus on Alzheimer's disease. Working through Cure Network Ventures, Inc., the new company will help expedite the translation of relevant scientific discoveries from the Gladstone Institute of Neurological Disease into the development of potential therapies. [More]
PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin). [More]
SutroVax completes $22 million Series A financing

SutroVax completes $22 million Series A financing

SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma's Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively. [More]
Experts draft prescription for making cancer drugs more affordable

Experts draft prescription for making cancer drugs more affordable

A group of 118 of the nation's leading cancer experts have drafted a prescription for reducing the high cost of cancer drugs and voiced support for a patient-based grassroots movement demanding action on the issue. Their recommendations and support are outlined in a commentary, co-authored by the group, in the journal Mayo Clinic Proceedings. [More]
Additional radiation to surrounding lymph nodes provides added benefit to breast cancer patients

Additional radiation to surrounding lymph nodes provides added benefit to breast cancer patients

A study has found no increase in overall survival but a reduction in breast cancer recurrence when additional radiation is given to the lymph nodes as well as the standard treatment of whole-breast irradiation after breast-conserving surgery. [More]
Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. [More]
New phase III cancer treatment trial opens for patient with advanced melanoma

New phase III cancer treatment trial opens for patient with advanced melanoma

A new phase III cancer treatment trial has opened for patient enrollment that examines two treatments that work in completely different ways yet have both been shown in previous clinical trials to be effective in treating patients with advanced melanoma, the ECOG-ACRIN Cancer Research Group announced today. [More]
Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine. [More]
Invuity's proprietary photonics technology recognized for improving patient safety

Invuity's proprietary photonics technology recognized for improving patient safety

Invuity, Inc., a leading surgical photonics company, today reported that The Joint Commission has recognized its proprietary photonics technology as an important innovation in the prevention of unintended retained foreign objects (URFOs) that are left inside patients during surgery. [More]
Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

Dauntless Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC today announced a licensing agreement providing Dauntless' access to Aegis' Intravail drug delivery technology for an undisclosed oncology application and an option for three additional drugs. [More]
MD Anderson ranked No. 1 hospital in nation for cancer care

MD Anderson ranked No. 1 hospital in nation for cancer care

The University of Texas MD Anderson Cancer Center has been ranked the No. 1 hospital for cancer care in the nation by U.S. News & World Report's "Best Hospitals" survey. [More]
New genomic fingerprint may predict prostate cancer risk in African American men

New genomic fingerprint may predict prostate cancer risk in African American men

African American men are more likely to develop prostate cancer than European American men, and are also more than twice as likely to die from it. Although there are many reasons that contribute to this health disparity, new research shows that African American men may have a distinctly different type of prostate cancer than European American men, according to new genomic fingerprinting results. [More]
MD Anderson researchers find high prevalence of hereditary CRC among people diagnosed before the age of 35

MD Anderson researchers find high prevalence of hereditary CRC among people diagnosed before the age of 35

Hereditary colorectal cancers, caused by inherited gene mutations, are relatively rare for most patients. However, researchers at The University of Texas MD Anderson Cancer Center have discovered a particularly high prevalence of hereditary cancers among those diagnosed with the disease before the age of 35. They suggest that these patients should undergo genetic counseling to determine if their families may be at an elevated risk. [More]
Patients' own genetically engineered immune cells show significant success against multiple myeloma

Patients' own genetically engineered immune cells show significant success against multiple myeloma

In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients' own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable. [More]
Advertisement